Formulary Search
Search Results : Hyperprolactinaemia (Cabergoline - Hyperprolactinaemia)
Show Icon and Status Keys
- Tablets
Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/
Ergot-derived dopamine agonists: risk of fibrotic reactions - GOV.UK
- Tablets
Cabergoline should be considered 1st-line. Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/
https://www.gov.uk/drug-safety-update/ergot-derived-dopamine-agonists-risk-of-fibrotic-reactions
- Tablets
Quinagolide tablets are scheduled for discontinuation between December 2026 and February 2027.
Clinicians are advised not to start new patients on this treatment. Existing patients may require specialist advice in relation to suitable alternatives